BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2025 6:10:11 AM | Browse: 302 | Download: 586
Publication Name World Journal of Clinical Oncology
Manuscript ID 110511
Country Italy
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Meta-Analysis
Article Title Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence
Manuscript Source Invited Manuscript
All Author List Ottavia Cicerone, Barbara Oliviero, Stefania Mantovani, Laura Maiocchi, Valentina Ravetta, Francesca Berton, Salvatore Corallo, Alessandro Vanoli and Marcello Maestri
ORCID
Author(s) ORCID Number
Ottavia Cicerone http://orcid.org/0009-0004-9712-2553
Marcello Maestri http://orcid.org/0000-0002-5693-9151
Funding Agency and Grant Number
Corresponding Author Marcello Maestri, MD, PhD, Professor, General Surgery Unit I - Liver Service, Fondazione IRCCS Policlinico San Matteo, P.le Golgi 19, Pavia 27100, Italy. m.maestri@smatteo.pv.it
Key Words Hepatocellular carcinoma; Neoadjuvant immunotherapy; Immune checkpoint inhibitors; Liver resection; Resectable hepatocellular carcinoma; Preoperative treatment
Core Tip This meta-analysis evaluates the efficacy and safety of neoadjuvant immunotherapy in resectable hepatocellular carcinoma (HCC). Pooled data suggest that this approach is feasible, with moderate pathological response rates and high resection feasibility, without a significant increase in severe toxicities. Although evidence is still limited, early findings support further investigation in prospective trials to define optimal treatment strategies and identify biomarkers predictive of response. Neoadjuvant immunotherapy may represent a promising strategy to improve surgical outcomes and reduce early recurrence in resectable HCC.
Publish Date 2025-10-24 06:10
Citation

Cicerone O, Oliviero B, Mantovani S, Maiocchi L, Ravetta V, Berton F, Corallo S, Vanoli A, Maestri M. Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence. World J Clin Oncol 2025; 16(10): 110511

URL https://www.wjgnet.com/2218-4333/full/v16/i10/110511.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i10.110511
Full Article (PDF) WJCO-16-110511-with-cover.pdf